Chemotherapy for recurrent/metastatic head and neck cancers
- 1 April 2017
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 28 (4), 357-361
- https://doi.org/10.1097/cad.0000000000000473
Abstract
Chemotherapy is the only option of treatment for most patients presenting with a recurrent and/or metastatic head and neck squamous cell carcinoma. The triple association of cisplatin, 5-fluorouracile, and cetuximab is still the current standard for fit patients. Other schemes are currently being compared with this protocol in ongoing trials and the association of cisplatin, docetaxel, and cetuximab appears to be the most efficient. The human papilloma virus is very likely a favorable prognostic factor. Immunotherapy with nivolumab or pembrolizumab is now a new standard of treatment in second line after yielding an improvement in overall survival, but predictive markers of efficacy are needed to refine the selection of patients. The combination of paclitaxel and buparlisib appears to be promising.Keywords
This publication has 25 references indexed in Scilit:
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialThe Lancet Oncology, 2013
- Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinomaAnti-Cancer Drugs, 2012
- Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinomaAnti-Cancer Drugs, 2012
- Resistance to EGFR-Targeted Therapy: A Family AffairCancer Cell, 2011
- Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatmentBritish Journal of Cancer, 2010
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based TherapyJournal of Clinical Oncology, 2007
- Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckCancer, 2005
- Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancerEuropean Journal of Cancer, 2004